Roquefort Investments PLC (GB:ROQ) has released an update.
Roquefort Therapeutics has been granted a European patent for its innovative Mesodermal Killer (MK) cell therapy, applicable in 39 countries, which promises to enhance immunotherapy treatments in oncology and immunology. The company is progressing in pre-clinical development, showing promising results in activating Natural Killer cells, potentially leading to more effective treatments. Additionally, Roquefort Therapeutics is advancing out-licensing deals for its Midkine antibody portfolio and STAT-6 siRNA program, indicating a potentially transformational period ahead.
For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.
